Comparative Pharmacology
Head-to-head clinical analysis: ALCAINE versus ALPHACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAINE versus ALPHACAINE.
ALCAINE vs ALPHACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
None Documented
None Documented
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Category C
Category C
Local Anesthetic
Local Anesthetic